Loading...
Loading...
Glanders is a rare but potentially fatal zoonotic infection caused by Burkholderia mallei, primarily affecting equines but capable of causing severe disease in humans through inhalation or skin contact. [1-2]
Exposure history: Contact with horses, mules, or other equines; laboratory work with B. mallei; potential bioterrorism exposure [1-3]
Onset and progression: Incubation period ranges from few days to several weeks [3]
Symptom characterization: Fever, rigors, malaise, cough, expectoration [3-4]
Route-specific symptoms:
Important negatives: Absence of recent travel to endemic areas, no known animal exposure
Rapid progression to sepsis and multi-organ failure [4]
Respiratory failure and acute respiratory distress syndrome [3]
Multiple organ abscesses (liver, spleen, lungs) [3]
Necrosis of tracheobronchial tree [3]
Disseminated infection with widespread abscess formation [3]
High mortality if untreated [2]
Effective antibiotics: Ceftazidime, gentamicin, imipenem, doxycycline, ciprofloxacin [1][5]
Combination therapy: Imipenem plus doxycycline (successful case report) [1][3]
Alternative agents: Meropenem, levofloxacin [4][6]
Contraindications: No specific contraindications beyond standard antibiotic allergies
Resistance concerns: Potential for engineered resistance in bioterrorism scenarios [3]
Hydration support during acute illness
Nutritional support for prolonged treatment course
No specific dietary restrictions related to glanders infection
Respiratory: Cough, dyspnea, chest pain, hemoptysis
Constitutional: Fever, chills, night sweats, weight loss, malaise
Dermatologic: Skin lesions, nodules, ulcerations, pustules
Lymphatic: Lymphadenopathy, particularly regional to entry site
Gastrointestinal: Nausea, vomiting, abdominal pain
Occupational exposure: Veterinary work, laboratory research, military service
Travel history: Areas with endemic glanders (rare in developed countries)
Animal contact: Recent exposure to horses, mules, donkeys
Family history: Generally not relevant (not person-to-person transmission)
Bioterrorism concerns: Multiple cases in unexpected setting [2]
Occupational exposure to equines or laboratory work [2-3]
Immunocompromised states (diabetes mellitus noted in case reports) [4]
Laboratory workers handling B. mallei [3]
Geographic factors: Areas with infected animal populations
Bioterrorism exposure scenarios [2]
Melioidosis (B. pseudomallei infection) - similar presentation and antibiotic susceptibility [5][7]
Pneumonic plague - rapid progression, bioterrorism concern
Tularemia - zoonotic infection with similar systemic features
Anthrax (inhalational) - bioterrorism agent with pulmonary involvement
Staphylococcal or streptococcal sepsis with abscesses
Tuberculosis - chronic pulmonary infection with systemic symptoms
Nocardiosis - similar abscess formation pattern
Diabetes mellitus (potential risk factor for severe disease) [4]
Immunosuppressive conditions or medications
Previous animal exposure or veterinary work
Laboratory work history with select agents
Military service or biodefense research background
Vital signs: Fever, tachycardia, hypotension in severe cases
Skin examination: Pustular lesions, ulcerating nodules, subcutaneous abscesses [1][3]
Lymph nodes: Regional lymphadenopathy with suppurative nodes [1][3]
Pulmonary: Consolidation, decreased breath sounds, pleural friction rub
Abdominal: Hepatosplenomegaly if disseminated infection [3]
Complete blood count: Leukocytosis with left shift
Blood cultures: May be positive in disseminated disease
Inflammatory markers: Elevated ESR, CRP
Liver function tests: Elevated if hepatic involvement
Arterial blood gas: Hypoxemia in pulmonary involvement
Specialized testing: PCR, multiplex gene sequencing [4][8]
Chest CT: Pulmonary consolidation, abscesses, pleural nodules, mediastinal lymphadenopathy [3-4]
Abdominal CT: Hepatic and splenic abscesses in disseminated disease [3]
Chest X-ray: May show pneumonic changes, less sensitive than CT
MRI: For suspected CNS involvement or soft tissue abscesses
Microbiological culture: Gold standard but may be negative [8]
PCR testing: More sensitive than culture, especially for respiratory samples [8]
Multiplex PCR-based gene sequencing: Rapid diagnostic method [4]
Serological testing: Complement fixation, ELISA, dipstick assays [9-10]
Tissue biopsy: Lymph node or lesion biopsy for diagnosis [4]
Generally not specific for glanders
May show tachycardia from sepsis or fever
Monitor for arrhythmias in severe sepsis
Rare but potentially fatal zoonotic infection [2]
High index of suspicion needed given rarity
Bioterrorism consideration in multiple unexplained cases [2]
Rapid progression possible with high mortality if untreated
Diagnosis challenging due to rarity and nonspecific symptoms
Initial intensive therapy: Ceftazidime or meropenem [7]
Combination therapy: Consider imipenem plus doxycycline [1][3]
Duration: Prolonged treatment required (weeks to months) [1]
Eradication therapy: Trimethoprim/sulfamethoxazole or amoxicillin/clavulanic acid [7]
Supportive care: Fluid resuscitation, respiratory support as needed
Admission criteria: All suspected cases require hospitalization
ICU consideration: Respiratory failure, sepsis, multi-organ involvement
Isolation precautions: Standard precautions (not person-to-person transmission)
Infectious disease consultation: Essential for management
Public health notification: Required for suspected bioterrorism
Close monitoring during treatment for treatment failure or complications
Repeat imaging to assess treatment response [4]
Long-term follow-up given prolonged treatment course
Return immediately for worsening respiratory symptoms, new fever, or signs of treatment failure
Complete full antibiotic course even if symptoms improve
Contact public health if multiple cases or bioterrorism suspected
1. Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the Infectious Diseases Society of America. — Stevens DL, Bisno AL, Chambers HF, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2014.
2. Glanders: An Overview of Infection in Humans. — Van Zandt KE, Greer MT, Gelhaus HC. Orphanet Journal of Rare Diseases. 2013.
3. Glanders in a Military Research Microbiologist. — Srinivasan A, Kraus CN, DeShazer D, et al. The New England Journal of Medicine. 2001.
4. A Case Report of Infection Leading to Pneumonia. — He G, Zeng Y, He Q, et al. Combinatorial Chemistry & High Throughput Screening. 2022.
5. In Vitro Susceptibilities of Burkholderia Mallei in Comparison to Those of Other Pathogenic Burkholderia SPP. — Kenny DJ, Russell P, Rogers D, Eley SM, Titball RW. Antimicrobial Agents and Chemotherapy. 1999.
6. Comparison of the in Vitro and in Vivo Susceptibilities of Burkholderia Mallei to Ceftazidime and Levofloxacin. — Judy BM, Whitlock GC, Torres AG, Estes DM. BMC Microbiology. 2009.
7. Workshop on Treatment of and Postexposure Prophylaxis for Burkholderia Pseudomallei and B. Mallei Infection, 2010. — Lipsitz R, Garges S, Aurigemma R, et al. Emerging Infectious Diseases. 2012.
8. Pathological Findings and Diagnostic Implications of a Rhesus Macaque (Macacca Mulatta) Model of Aerosol Exposure to Burkholderia Mallei (Glanders). — Yingst SL, Facemire P, Chuvala L, et al. Journal of Medical Microbiology. 2015.
9. Protein Microarray-Guided Development of a Highly Sensitive and Specific Dipstick Assay for Glanders Serodiagnostics. — Wagner GE, Berner A, Lipp M, et al. Journal of Clinical Microbiology. 2023.
10. Development of a Sensitive Competitive Enzyme-Linked Immunosorbent Assay for Serodiagnosis of Burkholderia Mallei, a Tier 1 Select Agent. — Wernery U, Chan E, Raghavan R, et al. PLoS Neglected Tropical Diseases. 2021.